pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice

[1]  V. Mathews,et al.  DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies , 2015, Oncotarget.

[2]  P. Fenaux,et al.  Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent , 2015, Leukemia.

[3]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[4]  M. Pla,et al.  Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: biomarker of long-term drug efficacy. , 2013, Molecular and cellular probes.

[5]  N. Warner,et al.  MyD88: A Critical Adaptor Protein in Innate Immunity Signal Transduction , 2013, The Journal of Immunology.

[6]  H. Heslop,et al.  High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. , 2011, Blood.

[7]  B. George,et al.  Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Pla,et al.  DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. , 2010, Blood.

[9]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[10]  L. Zitvogel,et al.  Immunogenic cancer cell death: a key-lock paradigm. , 2008, Current opinion in immunology.

[11]  H. Dombret,et al.  Frequent antibody production against RARα in both APL mice and patients , 2006 .

[12]  H. Dombret,et al.  Frequent antibody production against RARalpha in both APL mice and patients. , 2006, Blood.

[13]  J. Falkenburg,et al.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. , 2004, Blood.

[14]  M. Robin,et al.  PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia , 2003, Nature Medicine.

[15]  S. Kogan,et al.  Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia , 1999, The Journal of experimental medicine.

[16]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[17]  I. Weissman,et al.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Z A Arlin,et al.  Treatment of acute promyelocytic leukemia. , 1992, Blood.